One year in review
One year in review 2018: systemic lupus erythematosus
M. Di Battista1, E. Marcucci2, E. Elefante3, A. Tripoli4, G. Governato5, D. Zucchi6, C. Tani7, A. Alunno8
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Medicine, University of Perugia, Italy. alessia.alunno82@gmail.com
CER11391
2018 Vol.36, N°5
PI 0763, PF 0777
One year in review
Free to view
(click on article PDF icon to read the article)
PMID: 30272543 [PubMed]
Received: 09/05/2018
Accepted : 18/06/2018
In Press: 26/09/2018
Published: 26/09/2018
Abstract
Systemic lupus erythematosus (SLE) is a systemic autoimmune condition characterised by a wide spectrum of clinical manifestations, partly related to the disease itself, but also linked to its comorbidities and drugs adverse reactions. Following the previous annual reviews, we focused on new insights in SLE clinical features, pathogenic pathways, biomarkers of specific organ involvement and therapeutic strategies. We finally concentrated on SLE aspects that could significantly influence patients’ quality of life and that need to be investigated in detail through the development and validation of disease-specific patient-reported outcomes.
